Keyphrases
Adverse Events
33%
Between-group
33%
Brentuximab Vedotin
100%
Dose Intensity
16%
Japanese Patients
16%
Liver Dysfunction
16%
Median Overall Survival
16%
Median Progression-free Survival
16%
Metastatic Urothelial Carcinoma
100%
Multicenter Retrospective Study
100%
Multivariate Analysis
33%
Neutrophil-to-lymphocyte Ratio
16%
Objective Response Rate
33%
Old Japanese
16%
Older Patients
100%
Overall Survival
33%
Overall Survival Progression-free Survival
16%
Prognostic Factors
16%
Relative Dose Intensity
16%
Risk Factors
16%
Safety Profile
16%
Survival Response
16%
Young Patients
100%
Medicine and Dentistry
Adverse Event
40%
Enfortumab Vedotin
100%
Liver Dysfunction
20%
Lymphocyte
20%
Multivariate Analysis
40%
Neutrophil
20%
Overall Survival
80%
Prognostic Factor
20%
Progression Free Survival
40%
Retrospective Study
100%
Transitional Cell Carcinoma
100%